Ventricular Tachycardia Devices Market Report and Forecast 2025-2034

The global ventricular tachycardia devices market was valued at USD 1.83 Billion in 2024, driven by rising incidence of ventricular arrhythmias across the globe. It is expected to grow at a CAGR of 6.40% during the forecast period of 2025-2034 and attain a market value of USD 3.40 Billion by 2034.

Ventricular Tachycardia Devices Market Overview

Ventricular tachycardia devices include cardioverter-defibrillators (ICDs) and pacemakers, which are used to monitor and regulate fast heart rhythms coming from the ventricles. They play a vital role in controlling irregular heartbeats and avoiding unexpected heart failure. The market growth is fueled by the advancement in the treatment, increased investment, and support for cutting-edge research.

Ventricular Tachycardia Devices Market Growth Drivers

Rising Incidence of Ventricular Arrhythmias in Congenital Heart Disease to Drive the Market Growth

The increasing occurrence of ventricular arrhythmias in congenital heart disease is fueling the global demand for ventricular tachycardia devices, particularly in the pediatric population. The increasing prevalence of ventricular arrhythmias in patients with coronary heart disease showcases a greater need for medical devices such as pacemakers and defibrillators, leading to market expansion.

Advent of New Treatments to Boost the Ventricular Tachycardia Devices Market Demand

With the rising demand for treatments, the market for ventricular tachycardia devices is expanding. Technological and treatment advancement such as using exosomes from stem cells to improve treatments for venous thrombosis through cell-based therapy aims to overcome issues related to side effects and invasive procedures.

Ventricular Tachycardia Devices Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Focus on Aging Populations is Likely to Elevate the Market Value

A growing elderly male population susceptible to ventricular arrhythmia is driving the need for devices and treatments for this condition. The emphasis on addressing the needs of the elderly population and the health concerns that come with aging is one of the significant market trends impacting growth.

Increased Investment and Support for Cutting-Edge Research Affects the Market Landscape Significantly

The market is witnessing a rise in funding for cutting-edge research. For instance, CIRM received a USD 6 million grant for cardiovascular treatments, with a focus on stem cell therapies. This indicates an increasing trend in public and private funding for innovative treatments in the VT sector.

Increasing Emphasis on Personalized and Computational Cardiac Modeling

This market focuses on individualized heart care through computational modeling. By modeling patient-specific ventricular tachycardia patterns through 3D torso simulations, tailored diagnostics enhance the accuracy of ablation therapy, utilizing unique patient data for improved treatments and results in different heart conditions.

Rising Preference for Non-Invasive Diagnostics

The market is favoring non-invasive diagnostics. For instance, the application of cardiac implantable electronic devices to capture electrograms for identifying ventricular tachycardia demonstrates a shift towards non-invasive diagnostics, which minimizes risks and enhances the patient's experience.

Ventricular Tachycardia Devices Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product:

• Implantable Cardioverter Defibrillators (ICDs)
• Cardiac Resynchronization Therapy Defibrillators (CRT-D)
• Directed Energy-Based Therapy Devices

Market Breakup by End User:

• Hospitals
• Ambulatory Surgical Centers

Market Breakup by Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Ventricular Tachycardia Devices Market Share

Market Segmentation Based on the Product to Witness Growth

Based on the product, the market is segmented into implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy defibrillators (CRT-D), and directed energy-based therapy devices. Implantable cardioverter defibrillators are expected to lead the market as they can both act as pacemakers and prevent sudden death in patients with ventricular arrhythmias.

Ventricular Tachycardia Devices Market Analysis by Region

Based on region, the market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. The region that is most likely to dominate the market is North America, with Europe closely behind. Ventricular tachycardia and fibrillation are leading factors in sudden cardiac death, accounting for approximately 300,000 deaths in the United States each year. The rising incidence of the condition in the region is contributing to market growth.

Leading Players in the Ventricular Tachycardia Devices Market

The key features of the market report include patent analysis, grant analysis, funding, and investment analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:

Medtronic plc

Medtronic plc, a medical technology company based in America and Ireland received the FDA approval to conduct a trial on its Affera mapping and ablation system and Sphere-9 catheter for managing sustained ventricular tachycardia. This marks a significant advancement in cardiac electrophysiology ablation procedures and reflects the company’s stronghold on the market.

Siemens Healthineers AG

Siemens Healthineers is a healthcare company based in Germany, focused on creating, developing, manufacturing, and delivering diagnostic imaging and clinical systems. Varian, a Siemens Healthineers subsidiary, started the RADIATE-VT1 clinical trial at the Washington University School of Medicine to assess cardiac radioablation for high-risk ventricular tachycardia patients.

Abbott Laboratories

Abbott Laboratories specializes in healthcare products, including pharmaceuticals, diagnostic systems, and nutrition. In January 2024, Abbott announced its entry into the global ventricular tachycardia devices market with its pulsed field ablation device, Volt, currently in clinical development. Targeting atrial fibrillation treatment, Volt aims to launch in the U.S. by 2026.

Biotronik SE & Co. KG

Biotronik, a Berlin-based multinational cardiovascular biomedical company, specializes in technology for cardiac rhythm management, electrophysiology, and vascular intervention. Notable for its implantable cardioverter-defibrillator devices like Inventra 7 VR-T DX and Acticor DX, the company plays a crucial role in the ventricular tachycardia device market, delivering electroshocks to treat tachycardia.

Other players in the market are Asahi Kasei Corporation, Elekta AB, Boston Scientific Corporation, EBR Systems, Inc., Johnson & Johnson, LivaNova plc, Thermedical, Inc., and Schiller AG.

Key Questions Answered in the Ventricular Tachycardia Devices Market Report

• What was the ventricular tachycardia devices market value in 2024?
• What is the ventricular tachycardia devices market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is the market segmentation based on the product?
• What is the market breakup based on end user?
• What are the major factors aiding the ventricular tachycardia devices market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the major drivers, opportunities, and restraints in the market?
• What are the major trends influencing the market?
• Which regional market is expected to dominate the market share in the forecast period?
• Which country is likely to experience elevated growth during the forecast period?
• Who are the key players involved in the ventricular tachycardia devices market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.